SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing aggressive momentum driven by growing institutional conviction that CPU demand is a critical, under-modeled component of the broader AI infrastructure buildout. The community is actively debating the stock's elevated valuation against its structural role in mobile-to-AI architecture, with traders focused on positioning around potential earnings catalysts and managing volatility in this high-beta semiconductor play.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc is generating significant community interest ahead of its upcoming earnings call, with investors closely watching for a potential turnaround driven by improved cost discipline, subscription growth, and advancements in AR and AI integration. The stock is experiencing high volatility as participants weigh these long-term catalysts against ongoing concerns regarding user growth and intense competition in the social media space.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is experiencing intense volatility and speculative fervor as investors position themselves ahead of the upcoming earnings report, with the community sharply divided between those betting on a major short squeeze and others bracing for a post-earnings sell-off. Sentiment is fueled by debate over the company's valuation versus its long-term potential in quantum computing, while technical traders closely monitor institutional volume and significant short interest as key drivers for near-term price swings.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corporation is experiencing intense volatility driven by significant institutional selling of a major shareholder's stake, though community members are debating whether this marks a final clearance of supply or a signal of deeper structural concerns. While some investors view the current price action as a tactical accumulation opportunity ahead of upcoming earnings and potential sector-wide interest, others remain skeptical about management's ability to drive sustained profitability.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as investors react to a powerful earnings beat characterized by massive year-over-year growth and exceptional profit margins driven by its AI-powered AXON engine. While the stock faces volatility and community debate over its software sector classification, bullish sentiment remains centered on its aggressive e-commerce expansion and strong cash flow generation.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is gaining significant momentum following NOAA's official ruling that its deep-seabed mining application is fully compliant, a key regulatory milestone that clears a path toward potential commercial operations by 2027. Community members are actively debating the stock's long-term potential as a critical player in U.S. mineral sovereignty and are closely watching for follow-up news regarding commercial agreements and federal permitting timelines.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and heavy short-interest pressure as investors weigh recent clinical data updates for its siRNA pipeline against ongoing regulatory uncertainties surrounding its core gene therapy franchise. While the community remains sharply divided, active discussions center on the company's attractive valuation relative to its revenue base and the potential for a short squeeze if upcoming earnings and regulatory filings provide the necessary momentum.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV investors are locked in a heated debate ahead of earnings, with bulls pointing to the Disney partnership and potential for a short squeeze, while bears argue that persistent subscriber losses and poor management justify the stock's significant decline. The community remains deeply divided, focusing heavily on whether the company can finally hit profitability or if it will continue its long-term downward trend.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is experiencing extreme volatility as investors weigh strong operational fundamentalsincluding a 200M share buyback and margin expansionagainst a controversial short report that the company has formally refuted. The community is actively debating the credibility of these allegations, with many viewing the sharp sell-off as a significant buying opportunity while others express frustration over the sustained pressure on the stock price.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing significant volatility and a sharp price correction as the market digests recent competitive concerns and profit-taking after a sustained rally. The community remains deeply divided, with many traders debating whether this is a structural breakdown or a temporary pullback before the company's next earnings report, while others highlight the stock's resilience as an edge-computing infrastructure player.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. 'We entered 2026 with clear...

Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?

ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

M&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPT

M&T Bank Corp purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and...

Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...

Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk

Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.

OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy

Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss...

Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Cwm LLC

Cwm LLC raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 230.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 240,536 shares of the biotechnology company's stock after purchasing...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned an average rating of "Hold" from the twenty-eight research firms that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a sell recommendation, thirteen have assign...

$SRPT Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $3.15 up 168.48% YoY
• Reported revenue of $730.8M down -1.89% YoY
• Sarepta Therapeutics reiterated its FY 2026 guidance for total net product revenues of $1.2 - $1.4B, and combined non-GAAP R&amp;D and SG&amp;A expenses of $800.0 - $900M.

Stocktwits

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $3.15 up 168.48% YoY
• Reported revenue of $730.8M down -1.89% YoY
• Sarepta Therapeutics reiterated its FY 2026 guidance for total net product revenues of $1.2 - $1.4B, and combined non-GAAP R&D and SG&A expenses of $800.0 - $900M.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

https://files.quartr.com/streams/2026-05-06/9a9b28db-48e1-4f66-b463-c27401a25b97/2/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

SRPT  Earnings Call

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Stocktwits Polls

Traders are closely watching the upcoming earnings report and conference call for news on guidance and pipeline progress.

Bulls are citing the high 30% short float and current market volatility as triggers for a potential short-term rally.

Investors are speculating on potential acquisition interest in the $45-$70 price range given the company's DMD franchise control.

Concerns remain regarding FDA leadership changes and the efficacy of current treatments following recent industry commentary.

Current Price	$23.03
Prev Close	$21.79
Open	$22.12
Dividend Yield	0.00%
50-Day Moving Average	$19.68
Beta	1.24
Avg. Volume	2.45M
PE Ratio	-2.58

52-Week High	$44.14
52-Week Low	$10.42
Market Capitalization	$2.29B
EPS (Annual)	-$7.13
Price to Book	2.01
Revenue Per Employee	$2.63M

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News

SRPTSarepta Therapeutics Inc